Trial Profile

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2025 According to Everest Medicines media release, Latest results(as of March 21, 2025) from this trial will be presented at nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 .
09 Jun 2025 According to Everest Medicines media release, data from this trial will be presented in a focused oral session at the 62nd Congress of the European Renal Association (ERA 2025).
09 Jun 2025 Results presented in the Everest Medicines Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com